Protein and Oligonucleotide Delivery Systems for Vaginal Microbicides Against Viral STIs

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2014 Oct 18

PMID 25323132

Citations 16

Authors

Jill M Steinbach

Affiliations

Soon will be listed here.

Abstract

Intravaginal delivery offers an effective option for localized, targeted, and potent microbicide delivery. However, an understanding of the physiological factors that impact intravaginal delivery must be considered to develop the next generation of microbicides. In this review, a comprehensive discussion of the opportunities and challenges of intravaginal delivery are highlighted, in the context of the intravaginal environment and currently utilized dosage forms. After a subsequent discussion of the stages of microbicide development, the intravaginal delivery of proteins and oligonucleotides is addressed, with specific application to HSV and HIV. Future directions may include the integration of more targeted delivery modalities to virus and host cells, in addition to the use of biological agents to affect specific genes and proteins involved in infection. More versatile and multipurpose solutions are envisioned that integrate new biologicals and materials into potentially synergistic combinations to achieve these goals.

Citing Articles

Mesh and layered electrospun fiber architectures as vehicles for Lactobacillus acidophilus and Lactobacillus crispatus intended for vaginal delivery.

Minooei F, Kanukunta A, Mahmoud M, Gilbert N, Lewis W, Lewis A Biomater Adv. 2023; 154:213614.

PMID: 37659215 PMC: 10873095. DOI: 10.1016/j.bioadv.2023.213614.

Release Kinetics of Metronidazole from 3D Printed Silicone Scaffolds for Sustained Application to the Female Reproductive Tract.

Herold S, Kyser A, Orr M, Mahmoud M, Lewis W, Lewis A Biomed Eng Adv. 2023; 5.

PMID: 37123989 PMC: 10136949. DOI: 10.1016/j.bea.2023.100078.

In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.

Minooei F, Fried J, Fuqua J, Palmer K, Steinbach-Rankins J Int J Nanomedicine. 2021; 16:1189-1206.

PMID: 33623382 PMC: 7894819. DOI: 10.2147/IJN.S287310.

Assessment of CafA Targeted BAR-Encapsulated Nanoparticles against Oral Biofilms.

Desai H, Mahmoud M, Tan J, Minooei F, Demuth D, Steinbach-Rankins J Pharmaceutics. 2020; 12(9).

PMID: 32882864 PMC: 7557775. DOI: 10.3390/pharmaceutics12090835.

Pharmaceutical Approaches to HIV Treatment and Prevention.

Yavuz B, Morgan J, Showalter L, Horng K, Dandekar S, Herrera C Adv Ther (Weinh). 2020; 1(6).

PMID: 32775613 PMC: 7413291. DOI: 10.1002/adtp.201800054.

References

Zhou J, Rossi J . Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther. 2011; 18(12):1134-8. PMC: 3388903. DOI: 10.1038/gt.2011.149. View

Mallipeddi R, Rohan L . Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2009; 7(1):37-48. DOI: 10.1517/17425240903338055. View

Alam M, Ahmad F, Khan Z, Khar R, Ali M . Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections. AAPS PharmSciTech. 2008; 8(4):E109. PMC: 2750425. DOI: 10.1208/pt0804109. View

Mishra Y, Adelung R, Rohl C, Shukla D, Spors F, Tiwari V . Virostatic potential of micro-nano filopodia-like ZnO structures against herpes simplex virus-1. Antiviral Res. 2011; 92(2):305-12. PMC: 4148000. DOI: 10.1016/j.antiviral.2011.08.017. View

Kristensen D, Chen D . Stabilization of vaccines: Lessons learned. Hum Vaccin. 2010; 6(3). DOI: 10.4161/hv.6.3.11618. View

Looker K, Garnett G, Schmid G . An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008; 86(10):805-12, A. PMC: 2649511. DOI: 10.2471/blt.07.046128. View

Whitehead S, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, van de Wijgert J . Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand. PLoS One. 2011; 6(9):e14831. PMC: 3168444. DOI: 10.1371/journal.pone.0014831. View

Kredo T, Ford N, Adeniyi F, Garner P . Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev. 2013; (6):CD009987. PMC: 10009870. DOI: 10.1002/14651858.CD009987.pub2. View

Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B . Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res. 2004; 32(3):1154-8. PMC: 373410. DOI: 10.1093/nar/gkh278. View

10.

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

11.

Lai S, Wang Y, Wirtz D, Hanes J . Micro- and macrorheology of mucus. Adv Drug Deliv Rev. 2009; 61(2):86-100. PMC: 2736374. DOI: 10.1016/j.addr.2008.09.012. View

12.

Braunstein S, van de Wijgert J . Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Womens Health (Larchmt). 2005; 14(5):424-33. DOI: 10.1089/jwh.2005.14.424. View

13.

Brinckmann S, da Costa K, van Gils M, Hallengard D, Klein K, Madeira L . Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. J Transl Med. 2011; 9:40. PMC: 3086860. DOI: 10.1186/1479-5876-9-40. View

14.

Sexton A, Drake P, Mahmood N, Harman S, Shattock R, Ma J . Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB J. 2005; 20(2):356-8. DOI: 10.1096/fj.05-4742fje. View

15.

Barton C, Kouokam J, Lasnik A, Foreman O, Cambon A, Brock G . Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2013; 58(1):120-7. PMC: 3910741. DOI: 10.1128/AAC.01407-13. View

16.

Tobian A, Quinn T . Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS. 2009; 4(4):294-9. PMC: 2752434. DOI: 10.1097/COH.0b013e32832c1881. View

17.

McCormack S, Ramjee G, Kamali A, Rees H, Crook A, Gafos M . PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010; 376(9749):1329-37. PMC: 2956883. DOI: 10.1016/S0140-6736(10)61086-0. View

18.

Acarturk F . Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul. 2009; 3(3):193-205. DOI: 10.2174/187221109789105658. View

19.

Kinlock B, Wang Y, Turner T, Wang C, Liu B . Transcytosis of HIV-1 through vaginal epithelial cells is dependent on trafficking to the endocytic recycling pathway. PLoS One. 2014; 9(5):e96760. PMC: 4022679. DOI: 10.1371/journal.pone.0096760. View

20.

Dasgupta G, Chentoufi A, Nesburn A, Wechsler S, BenMohamed L . New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines. 2009; 8(8):1023-35. PMC: 2760836. DOI: 10.1586/erv.09.60. View